

Formulations and Treatment Method for Senile Dementia

Type: Review Article

Received: June 22, 2026

Published: July 21, 2026

Christina Rahm*

DRC VENTURES LLC, USA

***Corresponding Author:** Christina Rahm, DRC VENTURES LLC, USA.

Citation:

Christina Rahm. "Formulations and Treatment Method for Senile Dementia". PriMera Scientific Surgical Research and Practice 8.1 (2026): 281-285.

Copyright:

© 2026 Christina Rahm. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Senile dementia represents a complex neurodegenerative condition driven by multiple overlapping biological mechanisms, including amyloid- β deposition, tau pathology, oxidative stress, neuroinflammation, vascular dysfunction, and blood-brain barrier disruption. Because of this multifactorial nature, therapeutic strategies have increasingly shifted away from single-target pharmacology toward integrated, formulation-driven approaches. This white paper examines evolving treatment methodologies that combine traditional pharmacological agents, disease-modifying biologics, advanced drug-delivery technologies, nutraceutical interventions, hormonal and psychiatric symptom management, and non-pharmacological care models.

Current pharmacological therapies, including cholinesterase inhibitors and NMDA receptor antagonists, remain foundational but demonstrate limitations when used alone. Advances in formulation science, such as transdermal, intranasal, and nanoparticle-based delivery systems, aim to improve central nervous system penetration, bioavailability, and tolerability while reducing systemic adverse effects. Disease-modifying therapies targeting amyloid and tau proteins highlight a transition toward pathophysiological treatment, though challenges related to timing, safety, and brain penetration persist.

Nanotechnology and multimodal delivery platforms represent a significant area of innovation, enabling targeted drug transport across the blood-brain barrier and supporting sustained therapeutic release. Complementary strategies incorporating herbal, nutraceutical, and traditional medicine models are also explored, particularly when enhanced by modern formulation technologies that improve stability and absorption. In addition, management of psychiatric symptoms, hormonal influences, and individualized non-pharmacological care strategies contribute to a more comprehensive therapeutic framework.

Overall, the findings emphasize that successful dementia management relies on multimodal, person-centered interventions that integrate biological targeting with advanced formulation science. Future therapeutic development will likely depend on collaborative approaches that combine pharmacology, delivery innovation, and holistic care strategies to address the complexity of senile dementia.

Introduction

Senile dementia is a progressive neurodegenerative syndrome most commonly expressed as Alzheimer's disease, accounting for approximately 60 to 80 percent of dementia cases worldwide. It is characterized by deterioration of memory, impaired executive function, behavioral changes, and gradual loss of autonomy. Neuropathological studies describe dementia as arising from interacting biological mechanisms, including amyloid- β aggregation, tau hyperphosphorylation, synaptic dysfunction, oxidative stress, neuroinflammation, vascular impairment, and disruption of the blood-brain barrier, as described by Koga-Batko et al. (2025) and Elmahboub and Elkordy (2024). These overlapping mechanisms help explain the limited effectiveness of single-target therapeutic approaches and the increasing interest in combination treatment strategies. As a result, senile dementia is a multidimensional disorder that requires complex therapeutic intervention.

Traditional Pharmacological Preparations

Pharmacological therapy for senile dementia has traditionally focused on correcting neurotransmitter imbalance associated with aging. Cholinesterase inhibitors, including donepezil, rivastigmine, and galantamine, increase synaptic acetylcholine levels and may temporarily improve cognition and daily functioning, as reported in formulation and bioavailability studies (Schurad et al., 2022). Recent research indicates that alternative delivery modalities, such as transdermal and intranasal rivastigmine formulations, improve tolerability, enhance central nervous system penetration, and reduce systemic adverse effects (Imam et al., 2024; Talens-Visconti et al., 2023). These advances reflect a shift toward formulation-based optimization rather than reliance solely on the discovery of new drugs. Optimized delivery systems can therefore improve the clinical performance of established pharmacotherapies.

The N-methyl-D-aspartate receptor antagonist memantine is widely used in moderate to severe dementia to reduce glutamate-induced excitotoxicity. Memantine preserves physiological signaling while selectively inhibiting pathological NMDA receptor overactivation, which helps limit neuronal damage, as described in pharmacokinetic studies by Vohra et al. (2023). Combination therapy using memantine alongside cholinesterase inhibitors has demonstrated improved functional outcomes compared with monotherapy, highlighting the importance of targeting multiple neurotransmitter systems. This practice reflects growing recognition of dementia as a multifactorial neurochemical condition. Neurotransmitter modulation remains a foundational treatment strategy, although it continues to evolve.

Disease-Modifying and Biological Therapies

Modern therapeutic development increasingly focuses on disease-modifying interventions that target amyloid and tau pathology. Monoclonal antibodies such as aducanumab and donanemab aim to reduce amyloid burden and influence downstream neurodegenerative pathways, as discussed by Fessel (2023) and Fessel (2024). Although clinical effects remain modest and safety considerations persist, these agents represent a conceptual transition from purely symptomatic management toward pathophysiological intervention. Challenges such as limited brain penetration and treatment initiation during later disease stages remain areas for continued development. Overall, disease-modifying therapies represent meaningful progress that requires further refinement.

Tau-focused interventions are also being explored because of the strong association between tau pathology and cognitive decline. Elmahboub and Elkordy (2024) describe advanced delivery strategies, including nanoparticle-based carriers, designed to improve intracellular targeting and enable sustained release of tau-modulating agents. These technologies address limitations of traditional biologics, such as rapid clearance and limited blood-brain barrier penetration. The evolution of such delivery systems highlights the importance of formulation science in maximizing therapeutic impact. Effective disease modification depends not only on molecular targeting but also on optimized delivery.

Nanotechnology-Based Drug Delivery Systems

The blood-brain barrier remains a major challenge in dementia treatment, limiting the ability of many therapeutic agents to reach

pathological regions of the brain. Nanotechnology-based drug delivery systems offer promising solutions by enhancing compound solubility, stability, bioavailability, and targeted delivery (Mir Najib Ullah et al., 2023). Polymer-based nanoparticles, lipid nanocarriers, dendrimers, and nano-emulsions have demonstrated improved brain penetration and controlled drug release in preclinical models. These systems may reduce peripheral toxicity while extending therapeutic duration. Nanotechnology therefore represents an important strategy for overcoming the limitations of traditional pharmacotherapy.

Plastic nanoparticles composed of PLGA, chitosan, or PEG-based polymers have gained attention due to their biocompatibility and predictable degradation profiles. Research indicates that nanoparticle-based formulations of rivastigmine, curcumin, and fucoxanthin may reduce amyloid aggregation, oxidative stress, and neuroinflammation while supporting cognitive function (Elmahboub & Elkordy, 2024; Salehi et al., 2020). Nose-to-brain delivery strategies further enhance targeting efficiency and bypass hepatic metabolism, as reported by Talens-Visconti et al. (2023). These findings emphasize formulation science as a driving force in therapeutic innovation. Nanocarriers play an important role in improving the performance of existing agents.

A complementary approach combining photobiomodulation with nanomedicine is also emerging. Ailioaie et al. (2023) report that neuromodulation using light may enhance mitochondrial activity and reduce inflammatory signaling, particularly when paired with nanoparticle-delivered therapeutics. This strategy illustrates the potential of multimodal interventions that integrate cellular energy metabolism with protein-targeted therapies. The additive or synergistic benefits of such integrative models may expand treatment possibilities beyond conventional pharmacology.

Herbal, Nutraceutical, and Traditional Formulations

Growing research into herbal and nutraceutical therapies reflects interest in safer and complementary treatment options. Compounds such as *Bacopa monnieri*, curcumin, essential oils, and berberine demonstrate antioxidant, anti-inflammatory, and cholinergic-modulating effects in systemic analyses conducted by Basheer et al. (2022) and Bommakanti et al. (2023). Although clinical evidence remains variable, these agents may offer adjunctive support, particularly during earlier disease stages. Limitations often relate to low bioavailability and inconsistent formulation quality, highlighting the need for modern delivery approaches to improve clinical relevance.

Traditional and Ayurvedic medicine models emphasize holistic management of senile dementia through dietary regulation, herbal formulations, and lifestyle modifications. Deshpande et al. (2025) suggest that Ayurvedic strategies may influence neuroendocrine balance and inflammatory pathways, supporting their integration into multimodal care. Nanoparticle-assisted delivery of herbal compounds has been proposed to enhance bioavailability and therapeutic consistency, as described by Durgapal et al. (2025). The combination of traditional knowledge with advanced formulation technology strengthens the scientific credibility of complementary therapies. Traditional formulations gain renewed relevance when supported by pharmaceutical innovation.

Psychiatric and Hormonal Symptom Management

Neuropsychiatric symptoms, including depression, agitation, and sleep disturbances, significantly affect dementia outcomes and caregiver burden. Trazodone has demonstrated effectiveness in managing depression and behavioral symptoms in elderly patients with dementia, with favorable tolerability profiles reported by Fagiolini et al. (2023). Addressing psychiatric symptoms pharmacologically may improve overall functioning even in the presence of cognitive decline. Symptom-oriented therapy therefore plays an important role in comprehensive dementia care.

Hormonal influences on dementia progression have also been explored, particularly in postmenopausal women. Meta-analyses indicate that hormone therapy administered during specific time windows may provide neuroprotective effects, as described by Nerattini et al. (2023) and Wu et al. (2020). However, risks associated with delayed treatment initiation highlight the need for individualized clinical decision-making. These findings underscore the importance of timing and formulation in therapeutic success. Hormonal modulation represents a potential option that requires careful consideration.

Non-Pharmacological and Formulation-Led Care Solutions

Non-pharmacological interventions remain essential components of dementia management. Psychological and behavioral symptoms may not respond adequately to medication alone, leading to the development of person-centered and formulation-based care models. James et al. (2023) and McKenna et al. (2022) demonstrate that multidisciplinary approaches incorporating caregiver education, environmental modification, and psychological formulation can reduce agitation and distress. These strategies emphasize understanding individual triggers rather than relying solely on pharmacological symptom control. Non-pharmacological therapies therefore address aspects of dementia that medication alone cannot fully manage.

Translating research evidence into clinical practice remains a significant challenge. James et al. (2020) propose implementation frameworks focused on staff education and systemic support to improve dementia care delivery. Such models promote consistency of care and reduce reliance on psychotropic medication. Organizational and educational interventions play a critical role in improving outcomes. Effective dementia management requires integration of both clinical and systemic factors.

Conclusion

Senile dementia is a multifactorial neurodegenerative disorder that requires integrated therapeutic approaches. Advances in pharmacological formulations, nanotechnology-based delivery systems, incorporation of herbal and traditional medicine, management of psychiatric symptoms, and non-pharmacological care models all contribute to improving treatment effectiveness. The convergence of biological targeting and formulation science continues to shape modern therapeutic strategies. Future progress will depend on multi-modal, person-centered, and formulation-driven interventions that address the complexity of dementia.

References

1. Ailioaie C, Ailioaie LM and Litscher G. "Photobiomodulation in Alzheimer's disease—A complementary method to state-of-the-art pharmaceutical formulations and nanomedicine?". *Pharmaceutics* 15.3 (2023): 916.
2. Basheer M, Sabu A and Thomas S. "Use of Bacopa monnieri in the treatment of dementia due to Alzheimer's disease: A systematic review of randomized controlled trials". *Interactive Journal of Medical Research* 11.2 (2022): e38542.
3. Bommakanti V, Suresh S and Reddy KR. "An overview of herbal nutraceuticals: Extraction, formulation, therapeutic effects, and potential toxicity". *Separations* 10.1 (2023): 177.
4. Deshpande S, Kulkarni A and Patil V. "Ayurvedic strategies for managing senile dementia: A systematic review. *Journal of Ayurveda and Integrative Medicine*". Advance online publication (2025).
5. Durgapal S, Kumar N and Tiwari P. "Unravelling the potential of essential oils for the management of dementia". *Discover Applied Sciences* 7 (2025): 98.
6. Elmahboub YSM and Elkordy AA. "Polymeric nanoparticles: A promising strategy for treatment of Alzheimer's disease". *Journal of Taibah University Medical Sciences* 19.3 (2024): 549-565.
7. Fagiolini A, Cuomo A and Frank E. "Trazodone in the management of major depression among elderly patients with dementia: A narrative review and clinical insights". *Neuropsychiatric Disease and Treatment* 19 (2023): 541-552.
8. Fessel J. "The several ways to authentically cure Alzheimer's dementia". *Ageing Research Reviews* 85 (2023): 101827.
9. Fessel J. "Formulating treatment to cure Alzheimer's dementia: Approach #2". *International Journal of Molecular Sciences* 25.7 (2024): 3524.
10. Imam SS, et al. "Formulation and characterization of polymeric nanoparticle of rivastigmine for effective management of Alzheimer's disease". *Saudi Pharmaceutical Journal* 32.4 (2024): 101879.
11. James IA, Blomberg K and Keady J. "Challenging behaviour in dementia care: A novel framework for translating knowledge to practice". *The Cognitive Behaviour Therapist* 13 (2020): e38.
12. James IA, McKenna J and Stephenson J. "Management of agitation in behaviours that challenge in dementia care: Multidisciplinary perspectives on non-pharmacological strategies". *Clinical Interventions in Aging* 18 (2023): 541-553.

13. James IA., et al. "Behavioural and psychological symptoms of dementia: A new framework for holistic understanding and non-pharmacological management". *BJPsych Advances* 28.1 (2022): 11-20.
14. Koga-Batko J., et al. "Nanoparticles as an encouraging therapeutic approach to Alzheimer's disease". *International Journal of Molecular Sciences* 26 (2025): 7725.
15. McKenna J, James IA and Blomberg K. Formulation-led care in care homes: Staff perspectives on this psychological approach. *International Journal of Older People Nursing* 17.2 (2022): e12426.
16. Mir Najib Ullah M, Uddin MS and Kabir MT. "Nanomedicine in the management of Alzheimer's disease: State-of-the-art". *Biomedicines* 11.1 (2023): 174.
17. Nerattini A, Orsolini L and Volpe U. "Menopause hormone therapy and Alzheimer's disease risk: A systematic review and meta-analysis". *Frontiers in Aging Neuroscience* 15 (2023): 1260427.
18. Salehi B., et al. "Curcumin's nanomedicine formulations for therapeutic application in neurological diseases". *Journal of Clinical Medicine* 9.2 (2020): 430.
19. Schurad B, Schmitt B and Müller WE. "Comparative bioavailability study of a novel multi-day rivastigmine transdermal patch". *Current Alzheimer Research* 19.5 (2022): 541-552.
20. Taléns-Visconti R, Pineda B and García-García E. "Intranasal drug administration in Alzheimer-type dementia". *Pharmaceutics* 15.5 (2023): 1399.
21. Vohra D, Kumar S and Sharma R. "Formulation strategies for nose-to-brain drug delivery in Alzheimer's disease". *Health Sciences Review* 6 (2023): 100056.
22. Wu J, Xu W and Wang Z. "Postmenopausal hormone therapy and Alzheimer's disease: A systematic review and time-response meta-analysis". *Pharmacological Research* 155 (2020): 104728.